Drug Profile
Research programme: diabetic retinopathy therapy - QuatRx Pharmaceuticals
Alternative Names: Diabetic retinopathy research programme - QuatRx PharmaceuticalsLatest Information Update: 20 Dec 2005
Price :
$50
*
At a glance
- Originator Hormos Medical; QuatRx Pharmaceuticals
- Developer Hormos Medical
- Class
- Mechanism of Action Neuropeptide Y receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetic retinopathy
Most Recent Events
- 20 Dec 2005 Discontinued - Preclinical for Diabetic retinopathy in Finland (Intravitreous)
- 16 Jun 2005 Hormos Medical has been acquired and merged into QuatRx Pharmaceuticals
- 22 Jun 2004 The programme is available for licensing (http://www.hormos-med.com)